CUREVAC N.V. O.N.
Commented by Stefan Feulner on February 9th, 2021 | 08:00 CET
CureVac, Cardiol Therapeutics, Bayer - roaring profits!
The race for the best and most effective vaccine is in full swing. After BioNTech and its partner Pfizer, Moderna and AstraZeneca were approved in Europe, but there are always obstacles. Over the weekend, for example, South Africa announced that it is forgoing the AstraZeneca vaccine for the time being. The background to this is its supposedly lower efficacy with the B.1.351 virus mutation. Somewhat unnoticed, another vaccine manufacturer is moving into pole position through innovative collaborations.
Read
Commented by Carsten Mainitz on January 12th, 2021 | 10:28 CET
CureVac, Q&M Dental, Moderna - What you didn't know - really exciting!
The World Health Organization (WHO) recorded more than 235 Covid-19 vaccine projects worldwide since January 2020, but few projects make it across the finish line. Timing is a critical factor, and early entrants will divide the huge market among themselves. These include BioNTech/Pfizer, Moderna and AstraZeneca. Still in the "test phase" is Tübingen-based CureVac, which recently entered into a sales cooperation with Bayer. Information published yesterday is positive and suggests approval of the preparation by the beginning of the second quarter of 2021 at the latest. Away from vaccine manufacturers, other Corona profiteers exist with which investors can earn handsomely. Q&M Dental from Singapore is little known. Its subsidiary is one of nine government-approved Corona testing facilities. Also, Q&M supplies Asian neighboring countries with millions of its Corona testing. We inform you about the news and potentials of known and unknown players.
Read
Commented by Stefan Feulner on December 21st, 2020 | 07:50 CET
CureVac, EXMceuticals, Formycom - the undiscovered profiteers of the crisis!
The Corona pandemic continues to be the dominant topic of our time. Not a day goes by when new achievements in the fight against the pandemic come to public attention. The battle against Covid-19 is becoming a multi-billion-dollar business. In addition to the well-known profiteers, the vaccine manufacturers BioNTech and Pfizer, Moderna and AstraZeneca and many smaller companies are also profiting. Their potential is still largely unknown on the stock market and is far from being fully exploited.
Read
Commented by André Will-Laudien on December 10th, 2020 | 10:59 CET
AdTiger, Formycon, CureVac - Brilliant to the finish line!
It seems strange that a single company should be worth as much as all its colleagues in the industry put together. There is no such thing - there is! Yesterday, Tesla had a valuation of USD 625 billion at the start of the stock market - that's more than all other car manufacturers put together. Of course, Elon Musk's creature has not been a pure car manufacturer for a long time. Tesla is a high-tech Company, led by a visionary who brings a new great idea from his inner design studio to the light of day every few weeks. With his visions about essential facts of the human future, he is as creative as Karl Lagerfeld and as crazy as Jean-Paul Gaultier. But everyone is looking for the favor of their customers and genius is what we urgently need in a pandemic environment.
Read
Commented by Nico Popp on December 9th, 2020 | 14:16 CET
Valeo Pharma, CureVac, Moderna, Sartorius: high-flyers or latecomers?
The pandemic continues to spread: Germany is now facing a complete lockdown. Meanwhile, there is good news from the vaccine and drug manufacturers. There are several vaccines available, and from 2021 onwards, vaccination programs are to be implemented rapidly in all industrialized countries. Nevertheless, question marks remain: How long a vaccination will protect a person remains to be seen. For this reason, drugs and other measures to treat patients successfully remain essential. One of these drugs has just received approval from the Canadian regulatory authorities.
Read
Commented by Stefan Feulner on November 12th, 2020 | 10:03 CET
Alibaba, Silver Viper, Saturn Oil & Gas, CureVac: You need to know!
High fluctuation margins are currently being observed on the market. Due to the shift into cyclical stocks, especially tech stocks like Amazon, Alibaba or the Companies benefiting enormously from the Corona pandemic, like ZOOM or TeamViewer, are falling. Here, after a first commute, there are good buying opportunities. Gold and silver stocks should also be added to the watch list. The uncertainty is certainly not over.
Read
Commented by Nico Popp on October 16th, 2020 | 12:19 CEST
CureVac, BioNTech, Valeo Pharma: Where is there still potential?
The race for vaccines against Covid-19 is fierce. Every day there are new water level reports - from setbacks to breakthroughs, everything is there. The Tübingen-based Company CureVac recently started its phase study IIa in Peru and Panama. Around 700 people are taking part in it. The study aims to find suitable dosages for the vaccine. To this end, test persons are vaccinated twice within 28 days. Other competitors, such as BioNTech, are already testing their vaccine on more volunteers. BioNTech recently started its phase III study in South Africa and is testing the vaccine on more than 40,000 people worldwide.
Read
Commented by Mario Hose on September 23rd, 2020 | 09:05 CEST
BioNTech, CureVac, or Valeo Pharma: who brings the highest return to shareholders?
When the Corona Pandemic started in November 2019 in Wuhan, China, nobody could have guessed the extent of the disease. Socially, economically and politically, Covid-19 has turned the world upside down. With increasing knowledge in dealing with the coronavirus, people around the globe are trying to come to terms with the new state of affairs - as best they can. On the stock market, there are numerous opportunities for investors to participate in further development in the fight against serious diseases.
Read
Commented by Mario Hose on September 18th, 2020 | 06:00 CEST
BioNTech, CureVac, EXMceuticals - reaching their goal with government support
In the fight against the spread of the Corona Pandemic, a great deal of commitment is required from companies. This situation also offers the opportunity to rethink and change existing work processes and procedures. Product ranges are being expanded and new possibilities and active ingredients are being sought to combat Covid-19. Above all, the common good of all is the primary focus of political institutions and for this reason they are not letting research-based companies down and are attracting them with special permits and subsidies. Ultimately, everyone around the world will likely benefit from this.
Read
Commented by Mario Hose on September 11th, 2020 | 09:59 CEST
BioNTech, CureVac, Valeo Pharma - Growth after capital injection
Anyone working in the medical sector knows that the development of therapies and products usually costs a lot of time and especially a lot of money. In the race against the spread of the current Corona pandemic, there are major changes in the industry, because whoever comes to the market with a product first is de facto guaranteed high sales and profits. However, there is not much time left for the development of a vaccine against Covid-19 and to reduce the economic damage, researching companies have virtually unlimited amounts of money available. Whoever finds a solution against Covid-19 will certainly have the right team in the starting blocks in the fight against the subsequent Corona viruses.
Read